Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$1.57 - $3.33 $97,387 - $206,559
-62,030 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.09 - $7.16 $13,824 - $24,200
3,380 Added 5.76%
62,030 $266,000
Q2 2021

Aug 16, 2021

SELL
$6.87 - $9.16 $99,615 - $132,820
-14,500 Reduced 19.82%
58,650 $485,000
Q4 2020

Mar 01, 2021

SELL
$12.07 - $17.95 $39,831 - $59,235
-3,300 Reduced 4.32%
73,150 $885,000
Q3 2020

Nov 13, 2020

BUY
$14.16 - $19.45 $266,208 - $365,660
18,800 Added 32.61%
76,450 $1.24 Million
Q2 2020

Aug 14, 2020

BUY
$6.97 - $17.12 $401,820 - $986,968
57,650 New
57,650 $865,000

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $142M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.